Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Sporos Bioventures LLC
Headquarters: Houston, TX, United States of America
Website: http://www.sporosbio.com
Year Founded: 2020
Status: Private
BioCentury | Jul 26, 2022
Management Tracks
Rakhit to succeed Third Rock’s Celniker at Flare
Plus Generate hires Goldman Sachs veteran Jason Silvers as CFO, and updates from HotSpot, Berkeley Lights and more
BioCentury | Sep 29, 2021
Management Tracks
Rawat becomes president, CBO at Fusion
Plus: Sporos, Ajax, Nanocan and NeuroSense
BioCentury | Jun 4, 2021
Finance
June 3 Quick Takes: venBio’s new $550M fund, plus Innovent-AnHeart, Ajax, Scynexis and more
Just 15 months after closing its $394 million third fund, venBio has completed its $550 million Global Strategic Fund IV, a vehicle designed to invest in 12-15 start-ups and in some cases provide
BioCentury | May 26, 2021
Regulation
May 25 Quick Takes: Moderna to submit pediatric COVID vaccine data to regulators in early June; plus FDA guidance on bispecifics, TG, Asylia, Pieris, Nordic, Ziphius and Kyma
Moderna Inc. (NASDAQ:MRNA) will be the next company to bring a COVID-19 vaccine forward for authorization in adolescents, with plans to submit data from the Phase II/III TeenCOVE study of its COVID-19
Items per page:
1 - 4 of 4